FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205634221> ?p ?o ?g. }

• W4205634221 endingPage "708" @default.
• W4205634221 startingPage "697" @default.
• W4205634221 abstract "This study investigates the effects of PRAX-562 on sodium current (INa ), intrinsic neuronal excitability, and protection from evoked seizures to determine whether a preferential persistent INa inhibitor would exhibit improved preclinical efficacy and tolerability compared to two standard voltage-gated sodium channel (NaV ) blockers.Inhibition of INa was characterized using patch clamp analysis. The effect on intrinsic excitability was measured using evoked action potentials recorded from hippocampal CA1 pyramidal neurons in mouse brain slices. Anticonvulsant activity was evaluated using the maximal electroshock seizure (MES) model, and tolerability was assessed by measuring spontaneous locomotor activity (sLMA).PRAX-562 potently and preferentially inhibited persistent INa induced by ATX-II or the SCN8A mutation N1768D (half-maximal inhibitory concentration [IC50 ] = 141 and 75 nmol·L-1 , respectively) relative to peak INa tonic/resting block (60× preference). PRAX-562 also exhibited potent use-dependent block (31× preference to tonic block). This profile is considerably different from standard NaV blockers, including carbamazepine (CBZ; persistent INa IC50 = 77 500 nmol·L-1 , preference ratios of 30× [tonic block], less use-dependent block observed at various frequencies). In contrast to CBZ, PRAX-562 reduced neuronal intrinsic excitability with only a minor reduction in action potential amplitude. PRAX-562 (10 mg/kg po) completely prevented evoked seizures without affecting sLMA (MES unbound brain half-maximal efficacious concentration = 4.3 nmol·L-1 , sLMA half-maximal tolerated concentration = 69.7 nmol·L-1 , protective index [PI] = 16×). In contrast, CBZ and lamotrigine (LTG) had PIs of approximately 5.5×, with significant overlap between doses that were anticonvulsant and that reduced locomotor activity.PRAX-562 demonstrated robust preclinical anticonvulsant activity similar to CBZ but improved compared to LTG. PRAX-562 exhibited significantly improved preclinical tolerability compared with standard NaV blockers (CBZ and LTG), potentially due to the preference for persistent INa . Preferential targeting of persistent INa may represent a differentiated therapeutic option for diseases of hyperexcitability, where standard NaV blockers have demonstrated efficacy but poor tolerability." @default.
• W4205634221 created "2022-01-25" @default.
• W4205634221 creator A5003548386 @default.
• W4205634221 creator A5012492503 @default.
• W4205634221 creator A5012831609 @default.
• W4205634221 creator A5024722202 @default.
• W4205634221 creator A5049624485 @default.
• W4205634221 creator A5050430932 @default.
• W4205634221 creator A5084776650 @default.
• W4205634221 date "2022-01-17" @default.
• W4205634221 modified "2023-09-27" @default.
• W4205634221 title "The novel persistent sodium current inhibitor PRAX‐562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers" @default.
• W4205634221 cites W1606137504 @default.
• W4205634221 cites W1977479452 @default.
• W4205634221 cites W1986601214 @default.
• W4205634221 cites W1987398739 @default.
• W4205634221 cites W1997956247 @default.
• W4205634221 cites W2002812952 @default.
• W4205634221 cites W2017398416 @default.
• W4205634221 cites W2024087203 @default.
• W4205634221 cites W2049724011 @default.
• W4205634221 cites W2065476766 @default.
• W4205634221 cites W2095581992 @default.
• W4205634221 cites W2100418754 @default.
• W4205634221 cites W2112438385 @default.
• W4205634221 cites W2121613199 @default.
• W4205634221 cites W2414978139 @default.
• W4205634221 cites W2592509339 @default.
• W4205634221 cites W2610381892 @default.
• W4205634221 cites W2743692336 @default.
• W4205634221 cites W2775939341 @default.
• W4205634221 cites W2803860160 @default.
• W4205634221 cites W2898181423 @default.
• W4205634221 cites W2907366444 @default.
• W4205634221 cites W2954053957 @default.
• W4205634221 cites W3000087908 @default.
• W4205634221 cites W3000439708 @default.
• W4205634221 cites W3005760136 @default.
• W4205634221 cites W3110590681 @default.
• W4205634221 cites W4205634221 @default.
• W4205634221 doi "https://doi.org/10.1111/epi.17149" @default.
• W4205634221 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35037706" @default.
• W4205634221 hasPublicationYear "2022" @default.
• W4205634221 type Work @default.
• W4205634221 citedByCount "1" @default.
• W4205634221 countsByYear W42056342212022 @default.
• W4205634221 crossrefType "journal-article" @default.
• W4205634221 hasAuthorship W4205634221A5003548386 @default.
• W4205634221 hasAuthorship W4205634221A5012492503 @default.
• W4205634221 hasAuthorship W4205634221A5012831609 @default.
• W4205634221 hasAuthorship W4205634221A5024722202 @default.
• W4205634221 hasAuthorship W4205634221A5049624485 @default.
• W4205634221 hasAuthorship W4205634221A5050430932 @default.
• W4205634221 hasAuthorship W4205634221A5084776650 @default.
• W4205634221 hasBestOaLocation W42056342212 @default.
• W4205634221 hasConcept C134018914 @default.
• W4205634221 hasConcept C147944092 @default.
• W4205634221 hasConcept C15744967 @default.
• W4205634221 hasConcept C169760540 @default.
• W4205634221 hasConcept C170493617 @default.
• W4205634221 hasConcept C17077164 @default.
• W4205634221 hasConcept C178790620 @default.
• W4205634221 hasConcept C185592680 @default.
• W4205634221 hasConcept C197934379 @default.
• W4205634221 hasConcept C2775858608 @default.
• W4205634221 hasConcept C2776414672 @default.
• W4205634221 hasConcept C2778186239 @default.
• W4205634221 hasConcept C2778375690 @default.
• W4205634221 hasConcept C2778802184 @default.
• W4205634221 hasConcept C2779253243 @default.
• W4205634221 hasConcept C42219234 @default.
• W4205634221 hasConcept C50952357 @default.
• W4205634221 hasConcept C537181965 @default.
• W4205634221 hasConcept C55493867 @default.
• W4205634221 hasConcept C71924100 @default.
• W4205634221 hasConcept C98274493 @default.
• W4205634221 hasConceptScore W4205634221C134018914 @default.
• W4205634221 hasConceptScore W4205634221C147944092 @default.
• W4205634221 hasConceptScore W4205634221C15744967 @default.
• W4205634221 hasConceptScore W4205634221C169760540 @default.
• W4205634221 hasConceptScore W4205634221C170493617 @default.
• W4205634221 hasConceptScore W4205634221C17077164 @default.
• W4205634221 hasConceptScore W4205634221C178790620 @default.
• W4205634221 hasConceptScore W4205634221C185592680 @default.
• W4205634221 hasConceptScore W4205634221C197934379 @default.
• W4205634221 hasConceptScore W4205634221C2775858608 @default.
• W4205634221 hasConceptScore W4205634221C2776414672 @default.
• W4205634221 hasConceptScore W4205634221C2778186239 @default.
• W4205634221 hasConceptScore W4205634221C2778375690 @default.
• W4205634221 hasConceptScore W4205634221C2778802184 @default.
• W4205634221 hasConceptScore W4205634221C2779253243 @default.
• W4205634221 hasConceptScore W4205634221C42219234 @default.
• W4205634221 hasConceptScore W4205634221C50952357 @default.
• W4205634221 hasConceptScore W4205634221C537181965 @default.
• W4205634221 hasConceptScore W4205634221C55493867 @default.
• W4205634221 hasConceptScore W4205634221C71924100 @default.
• W4205634221 hasConceptScore W4205634221C98274493 @default.
• W4205634221 hasIssue "3" @default.

• next